Compile Data Set for Download or QSAR
maximum 50k data
Found 830 with Last Name = 'volkmann' and Initial = 'ra'
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50081081(6-{4-[2-(4-Quinolin-8-yl-piperazin-1-yl)-ethyl]-ph...)
Affinity DataKi:  3nMAssay Description:Binding affinity of compound to human 5-hydroxytryptamine 1A receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50081081(6-{4-[2-(4-Quinolin-8-yl-piperazin-1-yl)-ethyl]-ph...)
Affinity DataKi:  11nMAssay Description:Binding ability of compound to human Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50081081(6-{4-[2-(4-Quinolin-8-yl-piperazin-1-yl)-ethyl]-ph...)
Affinity DataKi:  14nMAssay Description:Binding affinity of compound to human 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMuscarinic acetylcholine receptor M2(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50081082(2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-p...)
Affinity DataKi:  320nMAssay Description:Binding affinity of compound to m2 muscarinic receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281005(CHEMBL76445 | [(5R,6S)-7-Oxo-6-((R)-1-phenylacetox...)
Affinity DataKi:  400nMAssay Description:Inhibitory activity against human leukocyte elastase (HLE) was determinedMore data for this Ligand-Target Pair
In DepthDetails Article
TargetMuscarinic acetylcholine receptor M4(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50081082(2-(4-{2-[4-(6-Amino-pyridin-2-yl)-phenyl]-ethyl}-p...)
Affinity DataKi:  590nMAssay Description:Binding ability of compound to m4 muscarinic receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281006(CHEMBL72889 | [(5R,6S)-6-((R)-1-Hydroxy-ethyl)-7-o...)
Affinity DataKi:  1.50E+3nM Koff:  1.00E+3s-1Assay Description:Rate constant for the compound was determined (k2/ki) against human leukocyte elastase (HLE)More data for this Ligand-Target Pair
In DepthDetails Article
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281004(CHEMBL419820 | [(5R,6S)-6-((R)-1-Hydroxy-ethyl)-7-...)
Affinity DataKi:  3.20E+3nM Koff:  130s-1Assay Description:Rate constant for the compound was determined (k2/ki) against human leukocyte elastase (HLE)More data for this Ligand-Target Pair
In DepthDetails Article
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281003(CHEMBL306859 | [(5R,6S)-6-((R)-1-Hydroxy-ethyl)-7-...)
Affinity DataKi:  4.00E+3nM Koff:  170s-1Assay Description:Rate constant for the compound was determined (k2/ki) against human leukocyte elastase (HLE)More data for this Ligand-Target Pair
In DepthDetails Article
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281009(CHEMBL74813 | [(5R,6S)-6-((R)-1-Hydroxy-ethyl)-7-o...)
Affinity DataKi:  1.20E+4nMAssay Description:Inhibitory activity against human leukocyte elastase (HLE) was determinedMore data for this Ligand-Target Pair
In DepthDetails Article
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281007(CHEMBL75220 | [(5R,6S)-6-((R)-1-Hydroxy-ethyl)-7-o...)
Affinity DataKi: >1.00E+5nMAssay Description:Rate constant for the compound was determined (k2/ki) against human leukocyte elastase (HLE)More data for this Ligand-Target Pair
In DepthDetails Article
TargetNeutrophil elastase(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50281008(CHEMBL311390 | [(5S,6R)-6-((R)-1-Hydroxy-ethyl)-7-...)
Affinity DataKi: >1.00E+5nMAssay Description:Rate constant for the compound was determined (k2/ki) against human leukocyte elastase (HLE)More data for this Ligand-Target Pair
In DepthDetails Article
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370772(US10239835, Example 00324)
Affinity DataIC50:  4.41nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370754(US10239835, Example 00306)
Affinity DataIC50:  4.44nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370814(US10239835, Example 00365)
Affinity DataIC50:  5.24nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370813(US10239835, Example 00364)
Affinity DataIC50:  5.25nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370756(US10239835, Example 00308)
Affinity DataIC50:  5.72nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370745(US10239835, Example 00297)
Affinity DataIC50:  5.96nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370743(US10239835, Example 00295)
Affinity DataIC50:  6.20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370781(US10239835, Example 00333)
Affinity DataIC50:  6.81nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370815(US10239835, Example 00366)
Affinity DataIC50:  8.30nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370816(US10239835, Example 00367)
Affinity DataIC50:  8.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370769(US10239835, Example 00321)
Affinity DataIC50:  8.62nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370797(US10239835, Example 00349)
Affinity DataIC50:  8.78nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370802(US10239835, Example 00354)
Affinity DataIC50:  9.36nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370768(US10239835, Example 00320)
Affinity DataIC50:  9.60nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNitric oxide synthase, inducible(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50091800(2-amino-4-methylpyridine | 4-METHYLPYRIDIN-2-AMINE...)
Affinity DataIC50:  10nMAssay Description:In vitro inhibition of human inducible nitric oxide synthaseMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370744(US10239835, Example 00296)
Affinity DataIC50:  10.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237552(US10052306, 223 | rac-(3aR,5r,6aS)-5-(4- chloroben...)
Affinity DataIC50:  11.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238867(US10052306, 306 | rac-4-{2-[(3aR,5R,6aS)- 5-benzyl...)
Affinity DataIC50:  11.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238862(US10052306, 301 | rac-4-{2-[(3aR,5S,6aS)- 5-benzyl...)
Affinity DataIC50:  12.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237388(US10052306, 204 | rac-(3aR,5r,6aS)-2-(2- hydroxy-2...)
Affinity DataIC50:  12.6nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370676(US10239835, Example 00228)
Affinity DataIC50:  13nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238861(US10052306, 300 | rac-4-(2-((3aR,6aS)-5- benzylhex...)
Affinity DataIC50:  13.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370678(US10239835, Example 00230)
Affinity DataIC50:  14nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370782(US10239835, Example 00334)
Affinity DataIC50:  14.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237683(US10052306, 229 | rac-(3aR,5r,6aS)-5-(2- fluoroben...)
Affinity DataIC50:  15.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393276(5-(3,4- difluorobenzenesulfon- amidomethyl)-6- met...)
Affinity DataIC50:  16.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238865(US10052306, 304 | rac-4-{2-[(3aR,5S,6aS)- 5-benzyl...)
Affinity DataIC50:  16.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370755(US10239835, Example 00307)
Affinity DataIC50:  16.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235335(US10052306, 131 | US10052306, 281 | rac-(3aR,5r,6a...)
Affinity DataIC50:  17.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237322(US10052306, 168 | rac-(3aR,5r,6aS)-5-(4- fluoroben...)
Affinity DataIC50:  17.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370681(US10239835, Example 00233)
Affinity DataIC50:  17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370727(US10239835, Example 00279)
Affinity DataIC50:  17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370694(US10239835, Example 00246)
Affinity DataIC50:  18nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370809(US10239835, Example 00361)
Affinity DataIC50:  19.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237551(US10052306, 222 | rac-2-(2-(3-fluoro-4- hydroxyphe...)
Affinity DataIC50:  19.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393246(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-6...)
Affinity DataIC50:  19.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370817(US10239835, Example 00368)
Affinity DataIC50:  20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238863(US10052306, 302 | rac-4-{2-[(3aR,5R,6aS)- 5-benzyl...)
Affinity DataIC50:  20.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 830 total ) | Next | Last >>
Jump to: